All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.

2017-03-07T11:20:03.000Z

NICE guidance on panobinostat for MM patients after at least two previous treatments

Mar 7, 2017
Share:

Bookmark this article

On 27th January 2016 the National Institute of Health and Care Excellence (NICE) released guidance recommending the use of panobinostat, in combination with bortezomib and dexamethasone, for the treatment of adults with relapsed or relapsed and refractory [R/R] Multiple Myeloma [MM] who have received at least two previous regimens (including bortezomib and an immunomodulatory agent).

The main reason for this recommendation was cost efficiency as a result of the patient access scheme granted by Novartis for the use of panobinostat.

Key clinical evidence came from the PANORAMA-1 randomised controlled clinical trial (n=768), which compared panobinostat with a placebo on a background of a bortezomib and dexamethasone combination regime. An indirect comparison of panobinostat in combination with bortezomib and dexamethasone, with lenalidomide plus dexamethasone was also assessed, as well as a semi-Markov model comparing the cost-effectiveness of panobinostat with dexamethasone with lenalidomide plus dexamethasone.

The committee discussed concerns regarding the uncertainty of the evidence, such as the relevant age group and the fact that a large number of patients had received a stem-cell transplant, and had been receiving bortezomib for a long period. It was also noted that only a sub-group of patients fell into the category for which panobinostat has marketing authorisation (i.e. RRMM having had two or more previous treatments). Despite this, the results of the PANORAMA 1 trial were deemed relevant to NHS patients, and panobinostat in combination with bortezomib and dexamethasone was thought to be clinically effective.  

Taking into account all the evidence, the incremental cost-effectiveness ratio for panobinostat, in combination with bortezomib and dexamethasone, was deemed to be no higher than £25,000 per QALY gained.

In summary, due consideration was given to both the relevant clinical evidence, plus the calculated cost-effectiveness ratio for panobinostat in combination with bortezomib and dexamethasone, and outweighed the benefits of the current regime of lenalidomide plus dexamethasone, to treat RRMM patients that have received two or more previous treatments. This is in line with the approval of panobinostat granted by the EMA in August 2015.

  1. Hall CJ. et al. NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments. Lancet Oncol. 2016 Mar;17(3):279-80. DOI: 10.1016/S1470-2045(16)00061-9. Epub 2016 Jan 27.
  2. NICE. Technology appraisal guidance TA380. Panobinostat for treating multiple myeloma after at least 2 previous treatments. http://www.nice.org.uk/guidance/TA380 (accessed Jan 27, 2016).

Your opinion matters

Which dosing schedule for belantamab mafodotin do you think is optimal for providing an efficacy benefit while managing toxicities?
2 votes - 41 days left ...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox